SH, C., PY, L., PH, L., YJ, L., WH, W., YN, H., & JY, C. (2026). GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation. Diabetes research and clinical practice, 231, 113073. https://doi.org/10.1016/j.diabres.2025.113073
Chicago Style (17th ed.) CitationSH, Chan, Li PY, Li PH, Lin YJ, Wang WH, Huang YN, and Chen JY. "GLP-1 Receptor Agonist Use During Immune Checkpoint Inhibitor Therapy Is Associated with Mortality and Immune-Related Adverse Events Across Cancer Types in People with Type 2 Diabetes: A Target-Trial Emulation." Diabetes Research and Clinical Practice 231 (2026): 113073. https://doi.org/10.1016/j.diabres.2025.113073.
MLA (9th ed.) CitationSH, Chan, et al. "GLP-1 Receptor Agonist Use During Immune Checkpoint Inhibitor Therapy Is Associated with Mortality and Immune-Related Adverse Events Across Cancer Types in People with Type 2 Diabetes: A Target-Trial Emulation." Diabetes Research and Clinical Practice, vol. 231, 2026, p. 113073, https://doi.org/10.1016/j.diabres.2025.113073.
